Volume 19, Issue 7
July 2017
Cover image
Cover image
Dual mechanism of action for Toca 511 & Toca FC (images from patient samples) that is characterized in companion articles: “Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model” and “Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anti-cancer immunity” (beginning on pages 930 and 918, respectively). Maria Rodriguez-Aguirre and Dr. Florence Hofman are gratefully acknowledged.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 19, Issue 7, July 2017
Editorials
When less is better: care of the elderly with glioblastoma
Neuro-Oncology, Volume 19, Issue 7, July 2017, Page 879, https://doi.org/10.1093/neuonc/nox075
Toward more informative biomarker-based clinical trials in glioblastoma
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 880–881, https://doi.org/10.1093/neuonc/nox063
Is the immune response a friend or foe for viral therapy of glioma?
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 882–883, https://doi.org/10.1093/neuonc/nox082
Highlights from the Literature
Highlights from the Literature
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 884–886, https://doi.org/10.1093/neuonc/nox099
Reviews
Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 887–896, https://doi.org/10.1093/neuonc/now258
Impaired health-related quality of life in meningioma patients—a systematic review
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 897–907, https://doi.org/10.1093/neuonc/now250
Basic and Translational Investigations
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 908–917, https://doi.org/10.1093/neuonc/now312
Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 918–929, https://doi.org/10.1093/neuonc/nox038
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 930–939, https://doi.org/10.1093/neuonc/nox037
Genotype-based gene signature of glioma risk
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 940–950, https://doi.org/10.1093/neuonc/now288
VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 951–964, https://doi.org/10.1093/neuonc/now297
Clinical Investigations
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 965–975, https://doi.org/10.1093/neuonc/now257
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 976–985, https://doi.org/10.1093/neuonc/now272
Pediatric Neuro-Oncology
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 986–996, https://doi.org/10.1093/neuonc/now294
Neuroimaging
Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 997–1007, https://doi.org/10.1093/neuonc/now270
Letters to the Editor
Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 1008–1010, https://doi.org/10.1093/neuonc/nox042
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials—impact of psychogenic non-epileptic seizures
Neuro-Oncology, Volume 19, Issue 7, July 2017, Pages 1010–1011, https://doi.org/10.1093/neuonc/nox064
Response to the letter regarding the impact of psychogenic nonepileptic seizures and our seizure assessment tool
Neuro-Oncology, Volume 19, Issue 7, July 2017, Page 1011, https://doi.org/10.1093/neuonc/nox072
Society News
Forthcoming Meetings
Neuro-Oncology, Volume 19, Issue 7, July 2017, Page 1012, https://doi.org/10.1093/neuonc/nox098
Corrigendum
Corrigendum
Neuro-Oncology, Volume 19, Issue 7, July 2017, Page 1013, https://doi.org/10.1093/neuonc/nox060
